Virilizing ovarian tumor

From WikiMD's Wellness Encyclopedia

Virilizing ovarian tumor refers to a type of ovarian tumor that leads to the development of male physical characteristics in females, a condition known as virilization. These tumors are rare and can produce androgens, male sex hormones, which are responsible for the virilization symptoms. The most common types of virilizing ovarian tumors include Sertoli-Leydig cell tumor, Leydig cell tumor, and certain types of thecomas and fibromas that have luteinized cells capable of secreting androgens.

Symptoms and Diagnosis[edit | edit source]

The symptoms of virilization may include hirsutism (excessive hair growth in areas where hair is normally sparse or absent), deepening of the voice, male-pattern baldness, increased muscle mass, and cessation of menstruation (amenorrhea). In some cases, an enlarged clitoris (clitoromegaly) may also be observed. The diagnosis of a virilizing ovarian tumor typically involves a combination of medical history, physical examination, blood tests to measure hormone levels, and imaging studies such as ultrasound or MRI to identify the presence of a tumor.

Treatment[edit | edit source]

Treatment for virilizing ovarian tumors usually involves surgical removal of the tumor. In some cases, depending on the type and stage of the tumor, additional treatments such as chemotherapy or radiation therapy may be necessary. Early diagnosis and treatment are crucial to prevent the progression of virilization and to manage the potential malignancy of the tumor.

Epidemiology[edit | edit source]

Virilizing ovarian tumors are rare, and their exact incidence is difficult to determine. They can occur at any age but are most commonly diagnosed in women of reproductive age.

Prognosis[edit | edit source]

The prognosis for individuals with virilizing ovarian tumors largely depends on the type and stage of the tumor at diagnosis. Tumors that are detected early and are localized to the ovary have a favorable prognosis with appropriate treatment. However, tumors that have metastasized or are of a more aggressive subtype may have a less favorable outcome.


Contributors: Prab R. Tumpati, MD